Wake Spine & Pain Specialists PC

Wake Spine & Pain Specialists PC was paid $1.10M by Medicaid between Jan 2018 and Dec 2024, across 23 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 42% of everything it billed.

33Billing provider infoWAKE SPINE & PAIN SPECIALISTS PC
CARY, NC 27518

33aNPI1568696748assigned 05/04/2009

33bProvider typePain Medicine (Anesthesiology) Physician

28Total paid$1.10M

24GClaims34,338

24DCodes billed23

24AFirst – last monthJan 2018 – Dec 2024

Compared with peers

Next to other Pain Medicine (Anesthesiology) Physician providers in North Carolina

Rank by total paid#7 of 43

Median peer was paid$90K

This provider vs. median12×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	2,111	$61K
2019	2,061	$56K
2020	1,716	$47K
2021	4,546	$108K
2022	7,194	$248K
2023	8,919	$287K
2024incomplete	7,791	$297K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	42%	17,614	13,711	$468K
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	35%	9,565	7,918	$388K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	5.4%	1,000	751	$60K
99204	Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity	5.4%	846	659	$59K
95886		3.2%	695	582	$35K
95911		2.7%	279	235	$30K
64483		2.3%	348	217	$25K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	1.7%	141	101	$19K
99203	Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity	<1%	135	90	$6K
L0648	Lumbar-sacral orthosis, sagittal control, with rigid anterior and posterior panels, posterior extends from sacrococcygeal junction to t-9 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf	<1%	19	14	$3K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	47	39	$3K
99152		<1%	163	104	$3K

11 more codes

J1040	Injection, methylprednisolone acetate, 80 mg	<1%	281	$755.36
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	<1%	30	$677.60
97112	Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination	<1%	26	$577.75
97140	Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage)	<1%	46	$502.31
97110	Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion	<1%	48	$467.55
97530	Therapeutic activities, direct patient contact, each 15 minutes	<1%	26	$390.44
Q9966	Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml	<1%	2,442	$329.09
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	534	$216.04
J1030	Injection, methylprednisolone acetate, 40 mg	<1%	22	$64.47
J3301	Injection, triamcinolone acetonide, not otherwise specified, 10 mg	<1%	16	$60.11
G0396	Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes	<1%	15	$26.92

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialMAUCERI, BERNADETTE (OFFICE MANAGER)